Last reviewed · How we verify
ritonavir and saquinavir
At a glance
| Generic name | ritonavir and saquinavir |
|---|---|
| Sponsor | The HIV Netherlands Australia Thailand Research Collaboration |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- A Prospective Cohort of Children With HIV Infection
- Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma (PHASE2)
- Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children (PHASE2, PHASE3)
- Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315 (PHASE2)
- A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir (NA)
- Interactions of HIV Protease Inhibitors and Methadone in HIV-Infected Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: